Dosimetric Comparison of High-Dose-Rate Brachytherapy and Intensity-Modulated Radiation Therapy as a Boost to the Prostate

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 1, 2010, Pages 269-276

  Hermesse, Johanne ^a   Biver, Sylvie ^a   Jansen, Nicolas ^a   Lenaerts, Eric ^a   Nickers, Philippe ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CENTRE OSCAR LAMBRET   (France)

Author keywords

Boost; Brachytherapy; Dosimetric comparison; IMRT; Prostate cancer

Indexed keywords

BRACHYTHERAPY; DOSE-VOLUME HISTOGRAMS; EQUIVALENT DOSE; EXTERNAL BEAM RADIOTHERAPY; HIGH-DOSE RATE BRACHYTHERAPY; HOT SPOT; INTENSITY-MODULATED RADIATION THERAPY; MEAN DOSE; ORGANS AT RISKS; PROSTATE CANCERS;

DOSIMETERS; DOSIMETRY; ONCOLOGY; RADIOTHERAPY;

PHYSICAL THERAPY;

ARTICLE; BLADDER; BRACHYTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RECTUM; RISK ASSESSMENT; URETHRA;

ALGORITHMS; BRACHYTHERAPY; HUMANS; MALE; MOVEMENT; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; TUMOR BURDEN; URETHRA; URINARY BLADDER;

EID: 72049121865     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.046     Document Type: Article

References (41)

1. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
2. Pollack A., Hanlon A.L., Horwitz E.M., et al. Prostate cancer radiotherapy dose response: An update of the fox chase experience. J Urol 171 (2004) 1132-1136
3. Zelefsky M.J., Y Y., Fuks Z., et al. Long term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 1028-1033
4. Al-Mamgani A., Van Putten W., Heemsbergen W., et al. Update of Dutch Multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 980-988
5. Chism D.D., Horwitz E.M., Hanlon A.L., et al. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 55 (2003) 71-77
6. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
7. Zelefsky M.J., Fuks Z.V.I., Wolfe T., et al. Locally advanced prostatic cancer: Long-term toxicity outcome after three-dimensional conformal radiation therapy: A dose-escalation study. Radiology 209 (1998) 169-174
8. Corner C., Rojas A.M., Bryan L., et al. A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 441-446
9. Hoskin P.J., Motohashi K., and Bownes P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 84 (2007) 114-120
10. Martinez A.A., Gustafson G., Gonzales J., et al. Dose escalation using conformal high dose rate brachytherapy improves outcome in unfavourable prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 81-90
11. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
12. Fowler J.F., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
13. Fowler J.F., Ritter M.A., Chappell R.J., et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 53 (2003) 1093-1104
14. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
15. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol 19 (2007) 289-301
16. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
17. Guckenberger M., and Flentje M. Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: A review and future perspectives. Strahlenther Onkol 183 (2007) 57-62
18. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 330-337
19. Dearnley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
20. Aström L., Pedersen D., Mercke C., et al. Long term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 74 (2005) 157-161
21. Dinges S., Deger S., Koswig S., et al. High dose rate interstial with external beam irradiation for localized prostate cancer-results of a prospective trial. Radiother Oncol 48 (1998) 197-202
22. Martinez A., Gonzales J., Spencer W., et al. Conformal high dose rate brachytherapy improves biochemical control and specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169 (2003) 974-979
23. Deger S., Boemer D., Roigas J., et al. High dose rate brachytherapy with conformal radiation therapy of localized prostate cancer. Eur Urol 47 (2005) 441-448
24. Galalae R.M., Kovacs G., Schultze J., et al. Long-term outcome after elective irradiation of the pelvic lymhatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 81-90
25. Nickers P., Thissen B., Jansen N., et al. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: A dosimetric point of view. Radiother Oncol 78 (2006) 47-52
26. Pieters B.R., Van der Grient J.N.B., Blank L.E.C.M., et al. Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants. Radiother Oncol 80 (2006) 69-72
27. Nedervenn A., Langedijk J., and Hofman P. Detection of fiducial gold markers for automatic on-line megavoltage position verification using a marker extraction kernel (MEK). Int J Radiat Oncol Biol Phys 47 (2000) 1435
28. Junius S., Haustermans K., Bussels B., et al. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiother Oncol 2 (2007) 29
29. Mott J.H., Livsey J.E., and Logue J.P. Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol. Br J Radiol 77 (2004) 377-386
30. Villeirs G.M., Van Vaerenbergh K., Vakaet L., et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 181 (2005) 424-430
31. Beltran C., Herman M.G., and Brian D. Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods. Int J Radiat Oncol Biol Phys 70 (2008) 289-295
32. Langen K.M., Willoughby T.R., Meeks S.L., et al. Observation on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 53 (2008) 7073-7086
33. Happersett L., Mageras G., Zelefsky M., et al. A study of the effects of internal motion on dose escalation in conformal prostate treatments. Radiother Oncol 66 (2003) 263-270
34. Goitein M. The probability of controlling an inhomogeneously irradiated tumor. Evaluation of Treatment Plannind for Particle Beam Radiotherapy (1987), Radiotherapy Development Branch, National Cancer Institute, Bethesda, MD 1-17
35. Marignol L., Foley R., Southgate T.D., et al. Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: A highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro. J Gene Med 11 (2009) 169-179
36. Wang J.Z., Li X.A., and Mayr N.A. Dose escalation to combat hypoxia in prostate cancer: A radiobiological study on clinical data. Br J Radiol 79 (2006) 905-911
37. Kim Y., and Tomé W. Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans. Acta Oncologica 47 (2008) 906-916
38. Kim Y., and Tomé W. Risk-adaptive optimization: Selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys 66 (2006) 1528-1542
39. Söhn M., Alber M., and Yan D. Principal component analysis-based pattern analysis of dose-volume histograms and influence on rectal toxicity. Int J Radiat Oncol Biol Phys 69 (2007) 230-239
40. Pieters B.R., Van de Kamer J.B., Van Herten Y.R., et al. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 88 (2008) 46-52
41. SM cyberknife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70 (2008) 1588-1597